• Haemonetics Corporation (NYSE:HAE) sets to enhance its product line and market position through the acquisition of Vivasure Medical Limited.
• Barrington sets a price target of $93 for Haemonetics, indicating a potential upside of 13.37%.
• The acquisition of Vivasure Medical aims to bolster Haemonetics' capabilities in structural heart and endovascular procedures, funded with cash on hand.

Haemonetics Corporation (NYSE: HAE) is a prominent player in the medical technology sector, specializing in blood management solutions. The company is known for its innovative products that cater to various medical procedures. Haemonetics faces competition from other medical technology firms, but it continues to strengthen its position through strategic acquisitions and product development.

On January 12, 2026, Barrington set a price target of $93 for Haemonetics, while the stock was trading at $82.03. This suggests a potential upside of 13.37%. The stock's recent performance shows a decrease of 2.39%, with a trading range between $81.94 and $84.92. Over the past year, the stock has fluctuated between $47.32 and $87.32, indicating volatility.

Haemonetics recently announced its acquisition of Vivasure Medical Limited, an Ireland-based company. This acquisition, valued at €100 million upfront, with potential milestone payments of up to €85 million, aims to enhance Haemonetics' capabilities in structural heart and endovascular procedures. The acquisition will be funded with cash on hand, showcasing Haemonetics' financial strength.

Vivasure's PerQseal Elite system, a key addition to Haemonetics' offerings, is designed to close large-bore arterial and venous access sites using a bioabsorbable patch. This system supports sizes up to 26F and aims to streamline workflow while minimizing complications. The acquisition aligns with the growing demand for large-bore vascular access in the medical field.

Vivasure's PerQseal Elite system has already received CE Mark approval in Europe and has a Premarket Approval application submitted to the U.S. FDA. The ELITE arterial study demonstrated the system's ease of use and a 0% major complication rate at thirty days. This acquisition is expected to bolster Haemonetics' position in the cardiology sector.